DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/svm9mh/cytomegalovirus_h) has announced the addition of Global Markets Direct's new report "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2012', provides an overview of the Cytomegalovirus (HHV-5) Infections therapeutic pipeline. This report provides information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections. 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- A snapshot of the global therapeutic scenario for Cytomegalovirus (HHV-5) Infections.
- A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Cytomegalovirus (HHV-5) Infections therapeutics.
For more information visit http://www.researchandmarkets.com/research/svm9mh/cytomegalovirus_h
Source: Global Markets Direct